Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1 - PubMed (original) (raw)
Case Reports
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1
Naomi N Hunder et al. N Engl J Med. 2008.
Abstract
We developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused these cells into a patient with refractory metastatic melanoma who had not undergone any previous conditioning or cytokine treatment. We show that the transferred CD4+ T cells mediated a durable clinical remission and led to endogenous responses against melanoma antigens other than NY-ESO-1.
2008 Massachusetts Medical Society
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures
Figure 1. PET Scans Obtained before T-Cell Infusion and 2 Months after Infusion
Preinfusion positron-emission tomography (PET) reveals hypermetabolic lesions in the right lung and the left inguinal–iliac node that are consistent with metastases (arrowheads); the lesions colocalized to tumor nodules on computed tomography (CT). After infusion with NY-ESO-1–specific CD4+ T cells, PET scans show that the tumor nodules have regressed, and no evidence of disease can be detected. Uptake in liver, spleen, and bladder represents normal background signal and did not colocalize to any lesions on CT scans.
Figure 2. Persistence of Transferred NY-ESO-1–Specific CD4+ T-Cell Clones In Vivo
Quantitative polymerase-chain-reaction (PCR) assay with the use of clone-specific primers flanking the TCR–CDR3 region was used to determine the frequency of infused CD4+ T-cell clones among peripheral-blood mononuclear cells (PBMCs) in samples collected before infusion and at intervals after infusion until day 90. Results are represented as the number of T-cell clones per 1 million PBMCs and as a percentage of the total number of PBMCs at peak points and low points. As expected, the NY-ESO-1–specific CD4+ T-cell clone is undetectable in preinfusion PBMCs (sensitivity of detection, 1:100,000 cells). After infusion, the frequency of the infused CD4+ T-cell clone in vivo increased to almost 2% of all PBMCs and fluctuated between 0.7 and 3.0% during the next 12 weeks. The I bars denote standard errors.
Figure 3. Augmentation of T-Cell Responses to Melanoma-Associated Tumor Antigens
Antigen-specific T-cell responses to melanoma antigen recognized by T cells (MART-1), melanoma antigen 3 (MAGE-3), NY-ESO-1, and glycoprotein 100 (GP100) were evaluated in samples of peripheral-blood mononuclear cells (PBMCs) collected before infusion and at time points up to 12 weeks after infusion. Autologous dendritic cells (DCs) that were transfected with RNA-encoding tumor antigen were used to stimulate PBMCs in enzyme-linked immunospot assays. The frequency of the antigen-specific response is presented as the number of reactive spots per 100,000 PBMCs (squares). Parallel wells with DCs transfected with control RNA were used at each time point (diamonds). Each data point is an average of the values from triplicate wells. After infusion, marked elevations in antigen-specific T-cell responses were observed for MAGE-3 (Panel A), MART-1 (Panel B), and NY-ESO-1 (Panel C) but not for GP100 (Panel D). The I bars denote standard errors.
Comment in
- Cancer immunotherapy--the endgame begins.
Weiner LM. Weiner LM. N Engl J Med. 2008 Jun 19;358(25):2664-5. doi: 10.1056/NEJMp0803663. N Engl J Med. 2008. PMID: 18565858 Free PMC article. No abstract available. - Cancer immunotherapy.
Prestwich R, Vile R, Melcher A. Prestwich R, et al. N Engl J Med. 2008 Sep 4;359(10):1072; author reply 1073. N Engl J Med. 2008. PMID: 18777615 No abstract available. - Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma.
Hodi FS, Fisher DE. Hodi FS, et al. Nat Clin Pract Oncol. 2008 Dec;5(12):696-7. doi: 10.1038/ncponc1259. Epub 2008 Oct 14. Nat Clin Pract Oncol. 2008. PMID: 18852719
Similar articles
- Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.
Tsuji K, Hamada T, Uenaka A, Wada H, Sato E, Isobe M, Asagoe K, Yamasaki O, Shiku H, Ritter G, Murphy R, Hoffman EW, Old LJ, Nakayama E, Iwatsuki K. Tsuji K, et al. Cancer Immunol Immunother. 2008 Oct;57(10):1429-37. doi: 10.1007/s00262-008-0478-5. Epub 2008 Mar 1. Cancer Immunol Immunother. 2008. PMID: 18311489 Free PMC article. - Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.
Kitano S, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z, Allison JP, Gnjatic S, Yuan JD, Wolchok JD. Kitano S, et al. Cancer Immunol Res. 2013 Oct;1(4):235-44. doi: 10.1158/2326-6066.CIR-13-0068. Cancer Immunol Res. 2013. PMID: 24396833 Free PMC article. - One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM. Mandic M, et al. J Immunol. 2005 Feb 1;174(3):1751-9. doi: 10.4049/jimmunol.174.3.1751. J Immunol. 2005. PMID: 15661941 - The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+ T Cells after Intercellular Antigen Transfer.
Fonteneau JF, Brilot F, Münz C, Gannagé M. Fonteneau JF, et al. J Immunol. 2016 Jan 1;196(1):64-71. doi: 10.4049/jimmunol.1402664. Epub 2015 Nov 25. J Immunol. 2016. PMID: 26608910 Free PMC article. - Vaccination for malignant melanoma: recent developments.
Jäger D, Jäger E, Knuth A. Jäger D, et al. Oncology. 2001;60(1):1-7. doi: 10.1159/000055289. Oncology. 2001. PMID: 11150901 Review.
Cited by
- NY-ESO-1 antigen: A promising frontier in cancer immunotherapy.
Alsalloum A, Shevchenko JA, Sennikov S. Alsalloum A, et al. Clin Transl Med. 2024 Sep;14(9):e70020. doi: 10.1002/ctm2.70020. Clin Transl Med. 2024. PMID: 39275923 Free PMC article. Review. - Diagnostic Approach to IgG4-Related Retroperitoneal Fibrosis After Colorectal Cancer Surgery in a Patient With Normal IgG4 Levels: A Case Report.
Kakehi E, Matsumoto M, Sugiyama K, Okutani H, Kotani K. Kakehi E, et al. Cureus. 2024 Jul 5;16(7):e63894. doi: 10.7759/cureus.63894. eCollection 2024 Jul. Cureus. 2024. PMID: 39099960 Free PMC article. - CAR-T and other adoptive cell therapies for B cell malignancies.
Lu P, Hill HA, Navsaria LJ, Wang ML. Lu P, et al. J Natl Cancer Cent. 2021 Jul 10;1(3):88-96. doi: 10.1016/j.jncc.2021.07.001. eCollection 2021 Sep. J Natl Cancer Cent. 2021. PMID: 39036373 Free PMC article. Review. - Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors.
Espinosa-Carrasco G, Chiu E, Scrivo A, Zumbo P, Dave A, Betel D, Kang SW, Jang HJ, Hellmann MD, Burt BM, Lee HS, Schietinger A. Espinosa-Carrasco G, et al. Cancer Cell. 2024 Jul 8;42(7):1202-1216.e8. doi: 10.1016/j.ccell.2024.05.025. Epub 2024 Jun 20. Cancer Cell. 2024. PMID: 38906155 - Primary cerebral melanoma: An exceptional localization in a case report.
Sghier AB, Samba S, Bouabid M, Mouhib N, Berhili S, Moukhlissi M, Mezouar L. Sghier AB, et al. Radiol Case Rep. 2024 Feb 13;19(5):1674-1678. doi: 10.1016/j.radcr.2024.01.049. eCollection 2024 May. Radiol Case Rep. 2024. PMID: 38384706 Free PMC article.
References
- Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol. 2006;24:5060–5069. - PubMed
- Mitchell MS, Darrah D, Yeung D, et al. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol. 2002;20:1075–1086. - PubMed
- Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol. 1991;49:281–355. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA104711-05/CA/NCI NIH HHS/United States
- CA1047113/CA/NCI NIH HHS/United States
- R21 CA128283-02/CA/NCI NIH HHS/United States
- M01 RR000037/RR/NCRR NIH HHS/United States
- R21 CA128283/CA/NCI NIH HHS/United States
- R01 CA104711/CA/NCI NIH HHS/United States
- M01 RR000037-47/RR/NCRR NIH HHS/United States
- CA12823/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials